Table 5 Comparison of groups according to depression score between baseline and 12 months post-treatment
No depression (n=47) | Change to non-depression (n=15) | Change to depression (n=12) | With depression (n=19) | p-value | |
|---|---|---|---|---|---|
Age | 31.0 [17.0, 61.0] | 30.0 [18.0, 49.0] | 26.0 [18.0, 55.0] | 32.0 [19.0, 48.0] | 0.454 |
Sex [Male] | 29 (61.7%) | 7 (46.7%) | 3 (25.0%) | 10 (52.6%) | 0.142 |
Heterozygous | 26 (55.3%) | 8 (53.3%) | 8 (66.7%) | 9 (47.4%) | 0.797 |
BMI (kg/m2) | 21.9 [16.2, 32.0] | 21.8 [17.4, 24.5] | 21.5 [18.5, 29.4] | 21.2 [18.1, 25.3] | 0.450 |
FEV1% | 67.0 [29.0, 108] | 71.0 [38.0, 114] | 58.0 [30.0, 93.0] | 54.0 [31.0, 102] | 0.157 |
Comorbility | |||||
Pancreatic insufficiency | 39 (83.0%) | 14 (93.3%) | 10 (83.3%) | 15 (78.9%) | 0.771 |
Hydrocarbon intolerance | 19 (40.4%) | 8 (53.3%) | 5 (41.7%) | 5 (26.3%) | 0.455 |
Hepatopathy | 11 (23.4%) | 5 (33.3%) | 3 (25.0%) | 3 (15.8%) | 0.696 |
Isolations | |||||
Pseudomonas aeruginosa | 18 (38.3%) | 4 (26.7%) | 7 (58.3%) | 6 (31.6%) | 0.353 |
Treatments | |||||
Previous Modulator | 21 (44.7%) | 6 (40.0%) | 2 (16.7%) | 11 (57.9%) | 0.156 |